Clovis Oncology Germany Gmbh

Rubraca rucaparib Tablets Now Owned by Pharma Schweiz GmbH

Clovis Oncology's Transfer of Ownership

Rubraca rucaparib tablets, previously marketed by Clovis Oncology, are now the property of Pharma Schweiz GmbH. This transfer of ownership marks a significant development in the pharmaceutical industry.

Clovis Oncology's Background

Clovis Oncology, an American pharmaceutical company based in Boulder, Colorado, specializes in developing and commercializing innovative therapies for oncology. Known for its focus on precision medicine, the company has a strong track record of developing targeted therapies for cancer treatment.

Pharma Schweiz GmbH's Acquisition

Pharma Schweiz GmbH, a Swiss pharmaceutical company, has acquired the rights to Rubraca rucaparib tablets. With this acquisition, Pharma Schweiz GmbH expands its portfolio of oncology drugs and strengthens its presence in the global oncology market.

Continued Availability of Rubraca

The acquisition of Rubraca rucaparib tablets by Pharma Schweiz GmbH ensures the continued availability of this important treatment option for patients with certain types of cancer. Patients who rely on Rubraca can rest assured that their access to this medication will not be affected.

Patient Support and Contact Information

For any questions regarding Rubraca rucaparib tablets, patients and healthcare professionals can contact Pharma Schweiz GmbH directly. The company provides comprehensive support and information on the proper use and storage of Rubraca.